Floatz logo

Pembrolizumab

Hepatocellular Carcinoma

Fudan Universitymonoclonal_antibodyPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
65/ 100

Competitive context

499 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Huaier Granule
Tongji Hospital
Phase 4BBB
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB
nrt6003
Second Affiliated Hospital of Guangzhou Medical University
Phase 3BB
Penpulimab
West China Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →